Last reviewed · How we verify
NCT02535845
Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial
NA trial testing Project Voice in Human Papillomavirus Vaccines in 22 participants. Terminated before completion.
31 January 2019
Quick facts
| Lead sponsor | University of Texas Southwestern Medical Center |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 22 |
| Start date | 21 December 2017 |
| Primary completion | 31 January 2019 |
| Estimated completion | 31 January 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Project Voice
- HPV Informational Video
Conditions studied
- Human Papillomavirus Vaccines — all drugs for Human Papillomavirus Vaccines →
Sponsor
University of Texas Southwestern Medical Center
Who can join
11 and older, any sex, with Human Papillomavirus Vaccines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
HPV vaccine coverage among adolescents in the US is suboptimal. This is particularly true among traditionally underserved adolescents. Few parent-targeted interventions have focused on the parental decision-making process. Self-persuasion, generating one's own arguments for engaging in a behavior, may be an effective means to influence parents' motivation to vaccinate their children. In a three-phase study, investigators are using quantitative and qualitative research methods to develop and refine a tablet-based self-persuasion intervention for parents who are undecided about the HPV vaccine. This clinical trial submission focuses on the third phase of the study (the second stage is also registered in clinical trials).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Developing a Tablet-Based Self-Persuasion Intervention Promoting Adolescent HPV Vaccination: Protocol for a Three-Stage Mixed-Methods Study.
Tiro JA, Lee SC, Marks EG, Persaud D, et al · · 2016 · cited 9× · PMID 26825137 · DOI 10.2196/resprot.5092
Verify or expand the search:
- PubMed search for NCT02535845
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Project Voice
Trials testing the same drug.
- NCT02537756 — Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination · NA · completed
Other University of Texas Southwestern Medical Center trials
Trials by the same sponsor.
- NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
- NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
- NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
- NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
- NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02535845 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
- Last refreshed: 30 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02535845.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing